Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 7/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.56 |
| ▸ | MEN1 | O00255 | 3/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.55 |
| ▸ | HCAR3 | P49019 | 3/20 | 0.53 |
| ▸ | GAA | P10253 | 3/20 | 0.53 |
| ▸ | GLA | P06280 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 2/20 | 0.52 |
| ▸ | LMNA | P02545 | 4/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.50 |
| ▸ | WNK1 | Q9H4A3 | 2/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | CRHBP | P24387 | 1/20 | 0.49 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.49 |
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30936578 | 1.00 | MAPT (0.56) | MAPTMAPK1MEN1KMT2AL3MBTL1 | |
| SCHEMBL11900769 | 0.95 | MAPT (0.57) | MAPTMAPK1MEN1KMT2AL3MBTL1 | |
| SCHEMBL10175331 | 0.92 | MAPT (0.60) | MAPTMAPK1MEN1KMT2AL3MBTL1 | |
| SCHEMBL9395556 | 0.88 | HCAR3 (0.64) | MAPTMAPK1MEN1KMT2AL3MBTL1 | |
| SCHEMBL550288 | 0.87 | MAPT (0.53) | MAPTMAPK1MEN1KMT2AL3MBTL1 | |
| SCHEMBL20334188 | 0.84 | HCAR3 (0.66) | MAPTMAPK1MEN1KMT2AL3MBTL1 | |
| SCHEMBL11901791 | 0.82 | MAPT (0.51) | MAPTMAPK1MEN1KMT2AL3MBTL1 | |
| SCHEMBL11901788 | 0.82 | MAPT (0.51) | MAPTMAPK1MEN1KMT2AL3MBTL1 | |
| SCHEMBL8884398 | 0.82 | ALDH1A1 (0.58) | MAPTMAPK1MEN1KMT2AL3MBTL1 | |
| SCHEMBL6482602 | 0.82 | HCAR3 (0.57) | MAPTMAPK1MEN1KMT2AL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250340510-A1 | Substituted Phenylbenzenesulfonamide Derivatives and Uses Thereof | NINE SQUARE THERAPEUTICS CORPORATION (US) | 2025-11-06 | — | — | US | disclosed |
| EP-4608389-A2 | SUBSTITUTED PHENYLBENZENESULFONAMIDE DERIVATIVES AND USES THEREOF | Nine Square Therapeutics Corporation (US) | 2025-09-03 | — | — | EP | disclosed |
| WO-2024092235-A2 | SUBSTITUTED PHENYLBENZENESULFONAMIDE DERIVATIVES AND USES THEREOF | NINE SQUARE THERAPEUTICS CORPORATION (US) | 2024-05-02 | — | — | WO | disclosed |
| CN-103476767-B | Heterocyclic compounds as PI3 kinase inhibitors | HOFFMANN LA ROCHE | 2015-06-10 | — | — | CN | disclosed |
| US-8653089-B2 | Heterocyclic compounds and methods of use | F. HOFFMANN-LA ROCHE AG (CH) | 2014-02-18 | — | — | US | disclosed |
| US-8653089-B2 | Heterocyclic compounds and methods of use | F. HOFFMANN-LA ROCHE AG (CH) | 2014-02-18 | — | — | US | disclosed |
| US-8653089-B2 | Heterocyclic compounds and methods of use | F. HOFFMANN-LA ROCHE AG (CH) | 2014-02-18 | — | — | US | disclosed |
| EP-2673269-A1 | HETEROCYCLIC COMPOUNDS AS PI3 KINASE INHIBITORS | F.HOFFMANN-LA ROCHE AG (CH) | 2013-12-18 | — | — | EP | disclosed |
| WO-2012107465-A1 | HETEROCYCLIC COMPOUNDS AS PI3 KINASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-08-16 | — | — | WO | disclosed |
| WO-2012107465-A1 | HETEROCYCLIC COMPOUNDS AS PI3 KINASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-08-16 | — | — | WO | disclosed |
| US-20120202785-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | F. HOFFMANN-LA ROCHE AG (CH) | 2012-08-09 | — | — | US | disclosed |
| US-20120202785-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | F. HOFFMANN-LA ROCHE AG (CH) | 2012-08-09 | — | — | US | disclosed |
| US-20120202785-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | F. HOFFMANN-LA ROCHE AG (CH) | 2012-08-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120202785-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | PIK3CA, PIK3CD, AKT3 | MAPT 1752/4885MAPK1 71/4885MEN1 2411/4885 |
| US-20250340510-A1 | Substituted Phenylbenzenesulfonamide Derivatives and Uses Thereof | TRPM2, TRPM6, TRPM5 | MAPT 39/4885MAPK1 1601/4885MEN1 2343/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.